Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16187959 | 1.00 | PIK3CD (0.32) | PIK3CDMAPK1 | |
| SCHEMBL16187939 | 1.00 | PIK3CD (0.32) | PIK3CDMAPK1 | |
| SCHEMBL2459380 | 0.88 | MAPK1 (0.40) | PIK3CDMAPK1 | |
| SCHEMBL23008584 | 0.79 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL21954704 | 0.79 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL18652867 | 0.78 | MAPK1 (0.33) | PIK3CDMAPK1 | |
| SCHEMBL25083738 | 0.78 | — | — | |
| SCHEMBL11273203 | 0.77 | — | — | |
| SCHEMBL18652869 | 0.76 | — | — | |
| SCHEMBL18508041 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | 280 Bio, Inc (US) | 2023-08-03 | — | — | US | disclosed |
| US-9765059-B2 | 5-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-20170044188-A1 | COPPER COMPOUND, STARTING MATERIAL FOR FORMING THIN FILM, AND METHOD FOR MANUFACTURING THIN FILM | ADEKA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20160304493-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-20 | — | — | US | disclosed |
| US-9403797-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-02 | — | — | US | disclosed |
| US-9353066-B2 | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-20 | — | — | US | disclosed |
| US-20150225372-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-13 | — | — | US | disclosed |
| US-9040540-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-20140315925-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| WO-2011114275-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304493-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CHEK1, CHEK2, PLK1 | PIK3CD 422/4885MAPK1 510/4885 |
| US-20170044188-A1 | COPPER COMPOUND, STARTING MATERIAL FOR FORMING THIN FILM, AND METHOD FOR MANUFACTURING THIN FILM | C5, C9, C1R | PIK3CD 2832/4885MAPK1 821/4885 |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | PIK3CD 358/4885MAPK1 204/4885 |
| US-20150225372-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CHEK1, CHEK2, PLK1 | PIK3CD 422/4885MAPK1 510/4885 |
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | NRAS, KRAS, RAB8A | PIK3CD 1365/4885MAPK1 95/4885 |
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | PIK3CD 374/4885MAPK1 600/4885 |
| US-20140315925-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CHEK1, CHEK2, PLK1 | PIK3CD 422/4885MAPK1 510/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | PIK3CD 97/4885MAPK1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.